Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)
出版年份 2015 全文链接
标题
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)
作者
关键词
-
出版物
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 42, Issue 7, Pages 829-844
出版商
Wiley
发表日期
2015-08-04
DOI
10.1111/apt.13342
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure
- (2015) M. Hedenstierna et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C
- (2015) K. Rutter et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review: patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens
- (2015) Z. Younossi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy
- (2014) M. H. Miller et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Combination of Alisporivir plus an NS5A Inhibitor Provides Additive to Synergistic Anti-Hepatitis C Virus Activity without Detectable Cross-Resistance
- (2014) Udayan Chatterji et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Acute pancreatitis associated with boceprevir: a case report
- (2014) Juliana Miguel Bilar et al. Brazilian Journal of Infectious Diseases
- Treatment of Hepatitis C
- (2014) Anita Kohli et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cyclophilin inhibition as potential therapy for liver diseases
- (2014) Nikolai V. Naoumov JOURNAL OF HEPATOLOGY
- Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial
- (2014) M. Buti et al. JOURNAL OF VIRAL HEPATITIS
- Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
- (2014) Ira M Jacobson et al. LANCET
- Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Michael Manns et al. LANCET
- Antiviral treatment of hepatitis C
- (2014) E. R. Feeney et al. BMJ-British Medical Journal
- First Report of Telaprevir-Induced Pancreatitis
- (2013) Carlos Ventura et al. DIGESTIVE DISEASES AND SCIENCES
- Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies
- (2013) Jianmeng Chen et al. GASTROENTEROLOGY
- Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics
- (2013) Anuoluwapo Osinusi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 821 INTERFERON (IFN)-FREE ALISPORIVIR (ALV) HAS A BETTER OVERALL SAFETY PROFILE COMPARED TO IFN-CONTAINING TREATMENT: A POOLED ANALYSIS OF THE ALV DEVELOPMENT PROGRAM
- (2013) L. Griffel et al. JOURNAL OF HEPATOLOGY
- Profile of alisporivir and its potential in the treatment of hepatitis C
- (2013) Philippe Gallay et al. Drug Design Development and Therapy
- Multiple Mutations in Hepatitis C Virus NS5A Domain II Are Required To Confer a Significant Level of Resistance to Alisporivir
- (2012) Jose A. Garcia-Rivera et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Validation of Multivariate Outlier Detection Analyses Used to Identify Potential Drug-Induced Liver Injury in Clinical Trial Populations
- (2012) Xiwu Lin et al. DRUG SAFETY
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
- (2012) Khayriyyah Mohd Hanafiah et al. HEPATOLOGY
- Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH)
- (2011) Paul B. Watkins et al. DRUG SAFETY
- The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction
- (2011) Giovanni Quarato et al. HEPATOLOGY
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanism of Resistance of Hepatitis C Virus Replicons to Structurally Distinct Cyclophilin Inhibitors
- (2010) X. Puyang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structural Basis for the Non-Immunosuppressive Character of the Cyclosporin A Analogue Debio 025
- (2010) Isabelle Landrieu et al. BIOCHEMISTRY
- DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A
- (2010) Lotte Coelmont et al. PLoS One
- Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor
- (2009) Kaku Goto et al. CANCER SCIENCE
- The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients
- (2009) Robert Flisiak et al. HEPATOLOGY
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
- (2009) John G. McHutchison et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now